Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib + Daunorubicin + Cytarabine in Newly Diagnosed AML
NCT05886049Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of revumenib in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoints: Recommended dose for expansion for Induction, Recommended dose for expansion for Consolidation and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05886049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886049.